| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| OR-2805 | OR-2805 | Phase 2 Clinical | OncoResponse Inc | Solid tumours; Leiomyosarcoma; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Liposarcoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma | Details |
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tetrachlorodecaoxide | TCDO; WF-10; OXO-K993 | Approved | Nuvox Pharma LLC | WF10, Oxoferin, Immunokine | Thailand | Rhinitis, Allergic; Inflammation | null | 1997-01-01 | Diabetic Foot; HIV Infections; Rhinitis, Allergic; Inflammation | Details |

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)
メールアドレス
order.jp@acrobiosystems.com
アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8



